It mediates important physiological effects of the endogenous peptide, GLP-1, in regulating insulin secretion, carbohydrate metabolism and appetite, and thus is well established as a long term clinical target for treating type II diabetes and obesity (Graaf et al
PR has received the following: consultancy and/or speaking fees (to his institution) from AbbVie, Abbott, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Novo Nordisk and Sanofi-Aventis, and research grants from AstraZeneca, Bayer and Novo Nordisk
Taneja denied these claims but the parties appear to be headed towards a settlement
Slowed Gastric Emptying : By slowing down the rate at which food leaves the stomach, GLP-1 medications can prolong feelings of fullness, making it easier to control food intake
India demonstrates the highest growth at 28.4%, supported by rising obesity prevalence in urban populations and increasing availability of treatment through private healthcare channels
